Login / Signup

Production and Functional Evaluation of Anti- Loxosceles Sera Raised by Immunizations of Rabbits with Mutated Recombinant Phospholipases-D.

Bruno Cesar AntunesNayanne Louise Costacurta PolliPedro Henrique de Caires SchlugaThais Pereira da SilvaAna Carolina Martins WilleRosangela Locatelli-DittrichGiovana Scuissiatto de SouzaFernando Hitomi MatsubaraJoão Carlos MinozzoAndrea Senff-RibeiroLuiza Helena GremskiSilvio Sanches Veiga
Published in: Biomedicines (2022)
Loxoscelism is the clinical condition triggered after the bite of spiders of the genus Loxosceles . The main species involved in accidents in South America are L. intermedia , L. laeta, and L. gaucho . The only specific treatment is the anti- Loxosceles serum produced with crude venoms. As phospholipases D (PLDs) trigger most of the effects observed in accidents, we developed and evaluated second-generation sera using mutated PLDs as antigens. Three isoforms of PLDs with site-directed mutations without biological activities were used for rabbit immunizations: D32A-E34A ( L. gaucho ), W230A ( L. intermedia ) , and H12A-H47A ( L. laeta ). Sera were produced using crude venoms of three species of Loxosceles enriched with mutated recombinant PLDs (MIX) or using only mutated PLDs (REC). Immunizations stimulated the immune system from the second immunization with higher antibody production in the REC group. In vivo neutralization assays demonstrated that both sera reduced edema and dermonecrosis caused by Loxosceles intermedia crude venom. Follow-up of animals during the immunization protocols and in the neutralization assays demonstrated that the mutated proteins and the sera are safe. Results demonstrate the potential of using mutated recombinant PLDs in total or partial replacement of Loxosceles venoms in animal immunizations to produce anti- Loxosceles sera for treatments of Loxoscelism.
Keyphrases
  • wild type
  • risk assessment
  • dendritic cells
  • immune response
  • combination therapy